Editorial commentary: Preserving myocardium in muscular dystrophy patients using ACE inhibition

Two of the key therapeutic questions for cardiology practitioners caring for muscular dystrophy patients is the efficacy and timing of initiating cardioprotective medications in this inexorably progressive disease. The article by Russo et al. [1] in this issue is an excellent review of this difficult and clinically important topic. The paper is a comprehensive review of angiotensin converting enzyme inhibitor (ACE-I) therapy in three different muscular dystrophies: Duchenne muscular dystrophy (DMD), myotonic dystrophy I, and Emery-Dreyfus muscular dystrophy.
Source: Trends in Cardiovascular Medicine - Category: Cardiology Authors: Source Type: research